Home >> Marketplace Archives >> HTG collaborates with BMS, 6/16

HTG collaborates with BMS, 6/16

Print Friendly, PDF & Email


June 2016—HTG Molecular Diagnostics entered into a research collaboration agreement with Bristol-Myers Squibb to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types. The collaboration will use the NGS-based HTG EdgeSeq system for use in support of Bristol-Myers Squibb’s translational research activities.

HTG Molecular Diagnostics, 877-289-2615


Check Also

Validation of blood test for heart transplant rejection, 12/13

December 2013—The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics are collaborating to begin clinical validation of a biomarker blood test that will provide early indication of organ rejection in heart transplant patients and thereby allow doctors to better monitor and treat patients post-transplant. It is the first clinical validation study of this kind in Canada.